Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

Last Funded December 2023

$366,884

raised from 223 investors
Pitch Video
Investor Panel

Highlights

1
CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
2
Corvidane raised $360k from over 200 Investors in previous RegCF.
3
Corvidane granted ~$700k in non-dilutive grants for Research and Development.
4
Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.

Our Team


Pitch





















Overview